MedTrace Logo

Measuring Fatty Liver With Ultrasound and MRS in Children With Overweight or Obesity

NCT03787108 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2019-03-21

No results posted yet for this study

Summary

Obesity is associated with a variety of comorbidities, amongst which non-alcoholic fatty liver disease (NAFLD). A recent meta-analysis has shown that the prevalence of NAFLD in obese pediatric populations is around 35%, compared to approximately 8% in general pediatric populations, making it a very important health threat in these populations. The golden standard for diagnosis of NAFLD is liver biopsy. However, since liver biopsy is associated with a certain risk of morbidity and mortality, this method is inappropriate for screening large populations at-risk for developing NAFLD. Magnetic resonance spectroscopy has demonstrated excellent correlation with liver biopsy and the is the most accuratete non-invasive method to measure liver fat content in children. However, MRS is expensive and not available in all centres. A novel ultrasonographic measurement to quantitatively assess liver steatosis is the hepatorenal index (HRI). Previous studies have shown high sensitivity and specificity of the HRI, as compared to MRS and liver biopsy. However, this measurement has never been validated in children. In this study, the HRI will be compared to MRS in children with obesity, to validate the HRI and to determine cut-off points.

Conditions

  • Non-Alcoholic Fatty Liver Disease

Interventions

OTHER

Magnetic resonance spectroscopy measurement

Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03787108 on ClinicalTrials.gov